5 Key Questions to Consider Before Sending Your Child Back to School

5 Key Questions to Consider Before Sending Your Child Back to School

Consider community, school district policies, family health, risks/benefits, and necessity of schools before making the difficult decision.

(© puhimec/Adobe)

[Editor's Note: This essay is in response to our current Big Question, which we posed to several experts: "Under what circumstances would you send a child back to school, given that the virus is not going away anytime soon?"]

Keep Reading Keep Reading
Megan L. Ranney
Dr. Megan L. Ranney is a practicing emergency physician, researcher, and advocate for innovative approaches to public health. She is Founding Director of the Brown-Lifespan Center for Digital Health, where her research focuses on using technology to improve adolescent mental health and reduce violence. She is also Chief Research Officer of AFFIRM Research, the country’s leading nonprofit committed to ending the gun violence epidemic through a non-partisan public health approach, and Co-Founder of GetUsPPE.org, a national nonprofit that gets donated personal protective equipment to healthcare workers in need. She is a Fellow of the fifth class of the Aspen Institute’s Health Innovators Fellowship Program.
Get our top stories twice a month
Follow us on
The Friday Five: Soon Band-Aids Could Be AIs

In this week's Friday Five, research on a "smart" bandage for wounds, a breakthrough in fighting inflammation, the pros and cons of a new drug for Alzheimer's, benefits of the Mediterranean diet with a twist, and we've learned to recycle a plastic that was un-recyclable.

Adobe Stock

The Friday Five covers five stories in research that you may have missed this week. There are plenty of controversies and troubling ethical issues in science – and we get into many of them in our online magazine – but this news roundup focuses on scientific creativity and progress to give you a therapeutic dose of inspiration headed into the weekend.

Keep Reading Keep Reading
Matt Fuchs

Matt Fuchs is the editor-in-chief of Leaps.org. He is also a contributing reporter to the Washington Post and has written for the New York Times, Time Magazine, WIRED and the Washington Post Magazine, among other outlets. Follow him on Twitter @fuchswriter.

Sexually Transmitted Infections are on the rise. This drug could stop them.

Cases of gonorrhea, chlamydia and syphilis soared last year, but researchers are finding that a drug known as doxy seems to reduce the number of infections.

Adobe Stock

Sexually transmitted infections (STIs) are surging across the U.S. to 2.5 million cases in 2021 according to preliminary data from the CDC. A new prevention and treatment strategy now in clinical trials may provide a way to get a handle on them.

It's easy to overlook the soaring rates of gonorrhea, chlamydia, and syphilis because most of those infections have few or no symptoms and can be identified only through testing. But left untreated, they can lead to serious damage to nerves and tissue, resulting in infertility, blindness, and dementia. Infants developing in utero are particularly vulnerable.

Keep Reading Keep Reading
Bob Roehr
Bob Roehr is a biomedical journalist based in Washington, DC. Over the last twenty-five years he has written extensively for The BMJ, Scientific American, PNAS, Proto, and myriad other publications. He is primarily interested in HIV, infectious disease, immunology, and how growing knowledge of the microbiome is changing our understanding of health and disease. He is working on a book about the ways the body can at least partially control HIV and how that has influenced (or not) the search for a treatment and cure.